Dilating the degradome: matrix metalloproteinase 2 (MMP-2) cuts to the heart of the matter
- 26 October 2004
- journal article
- editorial
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 383 (3) , E5-7
Abstract
With recent work revealing that MMPs (matrix metalloproteinases) cleave an increasingly large degradome of bioactive and signalling molecules, the dogma that MMPs are extracellular-matrix-remodelling proteases is under challenge. In this issue of the Biochemical Journal, Martínez et al. have reported that AM (adrenomedullin), a potent vasodilator predominantly expressed by blood vessel endothelial and smooth muscle cells, and microvasculature-rich tissues, is another new bioactive substrate for MMPs in vivo. Cleavage by MMP-2, but not MMP-9, generates a series of peptides; two of which retain receptor agonist and vasodilator activity, three are inactive and, excitingly, AM(11–22), a small product containing a canonical disulphide loop, is a vasoconstrictor. In view of the robust vasodilatory and other cardiac protective activities of AM in inhibiting myocardial fibrosis this represents a potent new systemic role for MMP-2 in the cardiovasculature. Hence, the paper by Martínez et al. directly implicates MMP activity in the development of hypertension and paradoxically in stimulating myocardial fibrosis, therefore pointing to exciting new possibilities for utilizing MMP-2-specific inhibitors as a new mode to treat blood pressure and heart disease.Keywords
This publication has 14 references indexed in Scilit:
- Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilatorBiochemical Journal, 2004
- Vascular Actions of Calcitonin Gene-Related Peptide and AdrenomedullinPhysiological Reviews, 2004
- Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1–matrix metalloproteinase substratesProceedings of the National Academy of Sciences, 2004
- HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegenerationNature Neuroscience, 2003
- Use of anti-neoepitope antibodies for the analysis of degradative events in cartilage and the molecular basis for neoepitope specificityBiochemical Society Symposia, 2003
- Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospectsExpert Opinion on Therapeutic Targets, 2003
- Strategies for MMP inhibition in cancer: innovations for the post-trial eraNature Reviews Cancer, 2002
- Matrix metalloproteinases: a tail of a frog that became a princeNature Reviews Molecular Cell Biology, 2002
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- Vasopeptidase InhibitorsCirculation, 2001